Ex vivo expansion of human T cells for adoptive immunotherapy using the novel Xeno‐free CTS Immune Cell Serum Replacement. Issue 1 (16th January 2015)

• Record Type: Journal Article
• Authors: Smith, Corey; Økern, Grethe; Rehan, Sweera; Beagley, Leone; Lee, Sau K; Aarvak, Tanja; Schjetne, Karoline W; Khanna, Rajiv
• Is Part Of: Clinical & translational immunology. Volume 4:Issue 1 (2015)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2015-01-16
• Subjects: Immunologic diseases -- Periodicals; Immunology -- Periodicals; Clinical medicine -- Periodicals; Immune System Diseases -- therapy; Immunotherapy; Immunologic Factors -- therapeutic use; Translational Medical Research; Molecular Targeted Therapy; Clinical medicine; Immunologic diseases; Immunology; Periodicals; Periodicals; Fulltext; Internet Resources; Periodicals; 616.079
• DOI: 10.1038/cti.2014.31
• Languages: English
• ISSNs: 2050-0068

Abstract

Abstract : The manufacture of clinical grade cellular products for adoptive immunotherapy requires ex vivo culture and expansion of human T cells. One of the key components in manufacturing of T cell therapies is human serum (HS) or fetal bovine serum (FBS), which can potentially expose immunotherapy recipient to adventitious infectious pathogens and are thus considered as non‐cGMP compliant for adoptive therapy. Here we describe a novel xeno‐free serum replacement (SR) with defined components that can be reproducibly used for the production of clinical grade T‐cell therapies in combination with several different cell culture media. Dynabeads CD3/CD28 Cell Therapy System (CTS)‐activated or antigen‐specific T cells expanded using the xeno‐free SR, CTS Immune Cell SR, showed comparable growth kinetics observed with cell culture media supplemented with HS or FBS. Importantly the xeno‐free SR supplemented medium supported the optimal expansion of T cells specific for subdominant tumour‐associated antigens and promoted expansion of T cells with central memory T‐cell phenotype, which is favourable for in vivo survival and persistence following adoptive transfer. Furthermore, T cells expanded using xeno‐free SR medium were highly amenable to lentivirus‐mediated gene transduction for potential application for gene‐modified T cells. Taken together, the CTS Immune Cell SR provides a novel platform strategy for the manufacture of clinical grade adoptive cellular therapies. Immunotherapy: Serum replacement for safer cells: A new source of nutrition for cells grown in culture could improve therapies against cancer and viruses that use cultured immune cells. Before being administered to patients in a procedure known as adoptive immunotherapy, immune cells called T‐cells are usually grown in a medium that contains human or bovine serum, but this serum poses a risk of infection. Researchers led by Rajiv Khanna from the QIMR Berghofer Medical Research Institute, Australia, tested whether human or bovine serum could be effectively replaced with an alternative called CTS™ Immune Cell Serum Replacement, which contains no non‐human derived material. T‐cells grew as well in medium that contained this replacement as they did in medium that contained serum, and costs were comparable. The serum replacement enables efficient growth of T‐cells that are safer for adoptive immunotherapy.